Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$9.35 USD

9.35
4,422,333

-0.26 (-2.71%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $51.67, marking a -0.27% move from the previous day.

Novavax (NVAX) Up as EMA Recommends COVID Jab for Adolescents

by Zacks Equity Research

EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to Novavax's (NVAX) COVID-19 vaccine for use in adolescents. The stock rises 13.9%.

The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

by Zacks Equity Research

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

FDA Committee Proposes EUA Nod to Novavax's (NVAX) COVID Jab

by Zacks Equity Research

An FDA advisory committee supports granting emergency use authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. Post the news, the stock rallies 20% in pre-market trading.

Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

by Zacks Equity Research

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novavax (NVAX) Down After FDA Raises Concern for Its COVID Jab

by Zacks Equity Research

Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.

Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates

by Zacks Equity Research

Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.

Novavax (NVAX) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -23.12% and 19.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) first-quarter earnings call, investor focus is likely to be on the sales figures of its COVID-19 vaccine.

BioNTech (BNTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q1 earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and updates on the non-CF pipeline.

Novavax (NVAX) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $45.07, moving +1.81% from the previous trading session.

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents

by Zacks Equity Research

Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.

Sanghamitra Saha headshot

Time for Reopening-Friendly Travel & Leisure ETFs?

by Sanghamitra Saha

As the pandemic is slowly turning into an endemic, leisure and travel stocks have flied higher.

Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study

by Zacks Equity Research

Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $54.59, marking a -1.03% move from the previous day.